protein_function: Acts as decoy receptor for TNFSF11,RANKL and therebyneutralizes its function in osteoclastogenesis. Inhibits theactivation of osteoclasts and promotes osteoclast apoptosis invitro. Bone homeostasis seems to depend on the local ratio betweenTNFSF11 and TNFRSF11B. May also play a role in preventing arterialcalcification. May act as decoy receptor for TNFSF10,TRAIL andprotect against apoptosis. TNFSF10,TRAIL binding blocks theinhibition of osteoclastogenesis..
Osteoprotegerin(OPG) is identical to osteoclastogenesis inhibitory factor(OCIF), a soluble member of the tumor-necrosis factor receptor family that inhibits osteoclastogenesis. OPG is considered to play an important role in the regulation of bone resorption by modifying osteoclast differentiation. Osteoprotegerin is an independent risk factor for the progression of atherosclerosis and onset of cardiovascular disease. It can act as a soluble factor in the regulation of bone mass and imply a utility for OPG in the treatment of osteoporosis associated with increased osteoclast activity. OPG system may play a critical role in the development of osteolytic bone disease in multiple myeloma and that targeting this system may have therapeutic potential. OPG also plays a role in the vascular system. The standard product used in this kit is recombinant OPG, a 55KDa glycoprotein.